Anti-CD20 antibody

The majority of patients with chronic lymphocytic leukemia ( CLL ) are older and have multiple comorbidities, including other cancer...


Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both...


The aim of the study was to assess dose-response effects of the anti-CD20 monoclonal antibody Ofatumumab on efficacy and safety...


The monoclonal anti-CD20 antibody Rituximab ( MabThera, Rituxan ), combined with chemotherapeutic agents, has been shown to prolong overall survival...


Rituximab ( MabThera, Rituxan ) is a chimeric murine/human monoclonal antibody that specifically targets CD20 molecules on the surface of...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration...


The first results from CLL11, a phase III study of the investigational medicine Obinutuzumab ( GA101; Gazyva ) were presented....


A new study has found for the first time that maintenance therapy with the novel antibody, Rituximab ( MabThera, Rituxan...


Roche has announced new Phase II efficacy data from the investigational compound GA101 ( RG 1759; Obinutuzumab ) in relapsed /...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis (...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In...


B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including rheumatoid arthritis. In...


A second generation, highly targeted monoclonal antibody appears to provide benefit for some patients with follicular lymphoma for whom other...